FACTOR VIII AND METHODS OF PREPARATION OF ITS CONCENTRATES

N. O. Shurko, M. I. Voroniak, T. V. Danysh


DOI: http://dx.doi.org/10.30970/sbi.0801.330

Abstract


To correct factor deficiency or prevent bleeding in patients with hemophilia A, the replacement therapy is carried out. This therapy involves administrating plasma or recombinant preparations of factor VIII. A variety of plasma- and recombinant-derived factor preparations are used for haemophilia treatment in Ukraine. Depending on purification level, the following types of plasma-derived concentrates are defined: intermediate purity products obtained through classic techniques of precipitation/adsorption, and high-purity concentrates purified through ion exchange or affinity chromatography. Since the late 1980s, recombinant factor drugs were brought into use in medical practice. They are synthesised by a genetically engineered Chinese hamster ovary cell line or baby hamster kidney. Recombinant factors are classified in generations according to the additional content of impurity human or animal proteins in a final product. The article provides an analysis of the main plasma-derived and recombinant factor VIII preparations registered in Ukraine. Basic properties, methods of preparation and methods of viral inactivation are described. The advantages and disadvantages of plasma-derived and recombinant products are generalized.


Keywords


blood coagulation, plasma and recombinant concentrate of factor VIII, chromatography, viral safety

References


1. Державний реєстр лікарських засобів України. On-line версія на веб-сайті www.drlz.kiev.ua

2. Зубаиров Д.М. Молекулярные основы свертывания крови и тромбообразования. Казань: Фен, 2000. 364 с.

3. Патент на винахід № 94299, Україна, МПК С07 1/22, С07К 14/755. Спосіб очищення фактора VIII згортання. Шурко Н.О., Даниш Т.В., Новак В.Л. Заявка № 2906990; Заявл. 03.07.2009 р.; Опубл 26.04.2011, Бюл. № 8. від 26.04.2011 р.

4. Патент на изобретение № (11)2445947, Россия, МПК С2(13), А61К38/37, А61К35/16. Способ получения концентрата фактора VIII из плазмы крови человека. Воробьев А.И., Берковский А.Л., Юрьев А.С. Заявка № 2010116125/15; Заявл. 26.04.2010; Опубл. 10.11.2010.

5. Ямкин А.В., Стронин О.В., Никитина Л.Н. Способ получения и свойства препарата VIII фактора свертывания плазмы крови человека. Сибирский медицинский журнал, 2009; 2(2): 17–20.

6. Calizzani G., Profili S., Candura F. et al. The demand for factor VIII and for factor IX and the toll fractionation product surplus management. Blood Тransfus, 2013; 11(4): 46-76.

7. Chandra S., Groener A., Feldman F. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. Thromb. Research, 2002; 105(5): 391-400.
https://doi.org/10.1016/S0049-3848(02)00044-0

8. Chtourou S., Porte P., Nogre M. A solvent/detergent treated and 15 nm filtered factor VIII: a new safety standard for pharma-derived coagulation factor concentrates. Vox Sang, 2007; 92 (4): 327-337.
https://doi.org/10.1111/j.1423-0410.2007.00892.x
PMid:17456157

9. De Waure C., Cadeddu C., Gualano M.-R. Gestione terapeutica dell'emofilia A. IJPH, 2011; 8(2): 17-30.

10. Iorio A., Halimeh S., Holzhauer S. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII сoncentrates: a systematic review. Thromb. Haemost, 2010; 8(6):1256-1265.
https://doi.org/10.1111/j.1538-7836.2010.03823.x
PMid:20345722

11. Josephson C.D., Abshire T. The new albumin free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement. Clin. Adv. Hematol. Oncol, 2004; 2(7): 441-446.

12. Kim In Seop, Yong Woon Choi. Dry-heat treatment process for enhancing viral safety of an antihemohpilic factor VIII concentrate preperated from human plasma. J. Microbiol. Biotechnol, 2008; 18(5): 997-1003.

13. Larsson P.-O. High-performance liquid affinity chromatography. Meth. Enzymol, 1984; 104: 213-223.
https://doi.org/10.1016/S0076-6879(84)04091-X

14. Mannucci P., Franchini M. Present and future challanges in the treatment of haemophilia: a clinician's perspective. Blood Тransfus, 2013; 11 (4): 77-81.

15. Marcel P.W.M. Te Booy, Anita Faber, Jan Over, Boudewijn W. Konig. Large scale purification of factor VIII by affinity chromatography: optimization of process parameters. J. Chromatogr, 1990; 8(2): 103-114.
https://doi.org/10.1016/S0021-9673(01)81494-1

16. Morfini M., Coppola A., Franchini M., Di Minno G. Clinical use of factor VIII and factor IX concentrates. Blood Тransfus, 2013; 11(4): 55-63.

17. Pat. 6953837US. Factor VIII/vWF complexes and compositions. M. Fischer, B. Schonberger, Thomas-Urban, K. Dorner, F. Eibl - Appl. N 10/003.621; Filed: 02.11. 2001; Publ. 11.10.2005.

18. Pat. 7166709US. Haemostatically active preparation containing vWF and method for the production thereof. Josic Stadler, Monika Gruber - Appl. N 10/257.375; Filed: April 04.04. 2001; Publ. 23.01.2007.

19. Pipe S.W. Recombinant clotting factor. Thromb. Haemost, 2008; 99(5): 840-850.
https://doi.org/10.1160/TH07-10-0593
PMid:18449413


Refbacks

  • There are currently no refbacks.


Copyright (c) 2014 Studia biologica

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.